Idenix Pharmaceuticals (IDIX)

[DewDiligence]

Viread / Truvada HBV Studies in Progress

[Excludes the large number of trials in HIV/HBV co-infected
patients. Studies sponsored by GILD except as noted. ]


First-line setting

Baraclude +/- Viread
(sponsored by BMY, 384 patients, recruiting):
http://www.clinicaltrials.gov/ct/show/NCT00410072

Viread vs Truvada
(100 patients, recruiting):
http://www.clinicaltrials.gov/ct/show/NCT00507507


Second-line setting

Viread vs Truvada in poor responders to Hepsera
(90 patients, enrollment complete):
http://www.clinicaltrials.gov/ct/show/NCT00307489

3-arm study in poor responders to Hepsera.
Arm A: Tyzeka + Hepsera
Arm B: Tyzeka + Viread
Arm C: Continued Hepsera monotherapy
(sponsored by NVS/IDIX, recruiting):
http://www.clinicaltrials.gov/ct/show/NCT00409019


Miscellaneous settings

Baraclude vs Viread/Truvada in decompensated liver disease.
Arm A: Viread
Arm B: Truvada
Arm C: Baraclude
(100 patients, recruiting):
http://www.clinicaltrials.gov/ct/show/NCT00298363

Truvada +/- Hepatitis B Immunoglobulin in patients with liver transplant
(50 patients, not yet recruiting):
http://www.clinicaltrials.gov/ct/show/NCT00507689